US 12286483
Method of treating cancer using CD137 antibodies and PD-1 antagonists
granted A61KA61K2039/507A61K39/001111
Quick answer
US patent 12286483 (Method of treating cancer using CD137 antibodies and PD-1 antagonists) held by Compass Therapeutics LLC expires Mon Apr 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Compass Therapeutics LLC
- Grant date
- Tue Apr 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Apr 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 22
- CPC classes
- A61K, A61K2039/507, A61K39/001111, A61K39/001117, A61P